Publication

Awareness among European healthcare professionals of four recent drug safety issues

de Vries, S., 3-Oct-2017, (Unpublished).

Research output: Contribution to conferencePosterAcademic

APA

de Vries, S. (2017). Awareness among European healthcare professionals of four recent drug safety issues. Poster session presented at FIGON Dutch Medicines Days, Ede, Netherlands.

Author

de Vries, Sietske. / Awareness among European healthcare professionals of four recent drug safety issues. Poster session presented at FIGON Dutch Medicines Days, Ede, Netherlands.

Harvard

de Vries, S 2017, 'Awareness among European healthcare professionals of four recent drug safety issues' FIGON Dutch Medicines Days, Ede, Netherlands, 02/10/2017 - 03/10/2017, .

Standard

Awareness among European healthcare professionals of four recent drug safety issues. / de Vries, Sietske.

2017. Poster session presented at FIGON Dutch Medicines Days, Ede, Netherlands.

Research output: Contribution to conferencePosterAcademic

Vancouver

de Vries S. Awareness among European healthcare professionals of four recent drug safety issues. 2017. Poster session presented at FIGON Dutch Medicines Days, Ede, Netherlands.


BibTeX

@conference{8b283a209e4d4b0a9fe48846237d79b9,
title = "Awareness among European healthcare professionals of four recent drug safety issues",
abstract = "Awareness among European healthcare professionals of four recent drug safety issuesPhD Sieta T. de Vries1, PhD Petra Denig1, PhD Peter G.M. Mol1,21Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, The Netherlands 2Dutch Medicines Evaluation Board, The NetherlandsBackgroundKnowledge of healthcare professionals’ (HCPs) awareness of specific drug safety issues and factors that are associated with awareness can help to improve safety communication strategies. This study aimed to assess European HCPs’ awareness of specific safety issues, sources through which HCPs had become aware, and which HCP characteristics are associated with awareness.MethodsIn the context of the Strengthening Collaboration for Operating Pharmacovigilance in Europe (SCOPE) Joint Action, a web-based survey was distributed among HCPs from nine European countries (i.e. Denmark, Spain, Croatia, Ireland, Italy, the Netherlands, Norway, Sweden, and the UK). HCPs were asked about awareness of the recent safety issues of combined hormonal contraceptives, diclofenac, valproate, and ivabradine. HCPs aware of a specific safety issue were additionally asked to indicate the source through which they had become aware. Associations between HCP characteristics (gender, profession, years of accreditation) and awareness of each of the safety issues were assessed using a penalized maximum likelihood logistic regression analysis per country.ResultsIn total, 3,620 HCPs were included ranging from 68 from Denmark to 1,075 from Spain. Awareness was highest for the diclofenac safety issue (91{\%}). Variation across the countries was largest for the ivabradine safety issue(range 24{\%} in Sweden to 87{\%} in Italy). Direct Healthcare Professional Communications were the main source of awareness followed by information on a website or in a newsletter but this differed across the countries. Of theassessed HCP characteristics, profession was mostly associated with awareness. Cardiologists were less aware than general practitioners, except for the ivabradine issue where cardiologists in the Netherlands were more aware than general practitioners (OR 8.79; 95{\%} CI 2.64-29.22).ConclusionIn several countries, additional strategies are needed to improve awareness of safety issues. DHPCs may not be sufficient to reach cardiologists when communicating safety issues of drugs outside their field.",
author = "{de Vries}, Sietske",
year = "2017",
month = "10",
day = "3",
language = "English",
note = "FIGON Dutch Medicines Days ; Conference date: 02-10-2017 Through 03-10-2017",

}

RIS

TY - CONF

T1 - Awareness among European healthcare professionals of four recent drug safety issues

AU - de Vries, Sietske

PY - 2017/10/3

Y1 - 2017/10/3

N2 - Awareness among European healthcare professionals of four recent drug safety issuesPhD Sieta T. de Vries1, PhD Petra Denig1, PhD Peter G.M. Mol1,21Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, The Netherlands 2Dutch Medicines Evaluation Board, The NetherlandsBackgroundKnowledge of healthcare professionals’ (HCPs) awareness of specific drug safety issues and factors that are associated with awareness can help to improve safety communication strategies. This study aimed to assess European HCPs’ awareness of specific safety issues, sources through which HCPs had become aware, and which HCP characteristics are associated with awareness.MethodsIn the context of the Strengthening Collaboration for Operating Pharmacovigilance in Europe (SCOPE) Joint Action, a web-based survey was distributed among HCPs from nine European countries (i.e. Denmark, Spain, Croatia, Ireland, Italy, the Netherlands, Norway, Sweden, and the UK). HCPs were asked about awareness of the recent safety issues of combined hormonal contraceptives, diclofenac, valproate, and ivabradine. HCPs aware of a specific safety issue were additionally asked to indicate the source through which they had become aware. Associations between HCP characteristics (gender, profession, years of accreditation) and awareness of each of the safety issues were assessed using a penalized maximum likelihood logistic regression analysis per country.ResultsIn total, 3,620 HCPs were included ranging from 68 from Denmark to 1,075 from Spain. Awareness was highest for the diclofenac safety issue (91%). Variation across the countries was largest for the ivabradine safety issue(range 24% in Sweden to 87% in Italy). Direct Healthcare Professional Communications were the main source of awareness followed by information on a website or in a newsletter but this differed across the countries. Of theassessed HCP characteristics, profession was mostly associated with awareness. Cardiologists were less aware than general practitioners, except for the ivabradine issue where cardiologists in the Netherlands were more aware than general practitioners (OR 8.79; 95% CI 2.64-29.22).ConclusionIn several countries, additional strategies are needed to improve awareness of safety issues. DHPCs may not be sufficient to reach cardiologists when communicating safety issues of drugs outside their field.

AB - Awareness among European healthcare professionals of four recent drug safety issuesPhD Sieta T. de Vries1, PhD Petra Denig1, PhD Peter G.M. Mol1,21Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, The Netherlands 2Dutch Medicines Evaluation Board, The NetherlandsBackgroundKnowledge of healthcare professionals’ (HCPs) awareness of specific drug safety issues and factors that are associated with awareness can help to improve safety communication strategies. This study aimed to assess European HCPs’ awareness of specific safety issues, sources through which HCPs had become aware, and which HCP characteristics are associated with awareness.MethodsIn the context of the Strengthening Collaboration for Operating Pharmacovigilance in Europe (SCOPE) Joint Action, a web-based survey was distributed among HCPs from nine European countries (i.e. Denmark, Spain, Croatia, Ireland, Italy, the Netherlands, Norway, Sweden, and the UK). HCPs were asked about awareness of the recent safety issues of combined hormonal contraceptives, diclofenac, valproate, and ivabradine. HCPs aware of a specific safety issue were additionally asked to indicate the source through which they had become aware. Associations between HCP characteristics (gender, profession, years of accreditation) and awareness of each of the safety issues were assessed using a penalized maximum likelihood logistic regression analysis per country.ResultsIn total, 3,620 HCPs were included ranging from 68 from Denmark to 1,075 from Spain. Awareness was highest for the diclofenac safety issue (91%). Variation across the countries was largest for the ivabradine safety issue(range 24% in Sweden to 87% in Italy). Direct Healthcare Professional Communications were the main source of awareness followed by information on a website or in a newsletter but this differed across the countries. Of theassessed HCP characteristics, profession was mostly associated with awareness. Cardiologists were less aware than general practitioners, except for the ivabradine issue where cardiologists in the Netherlands were more aware than general practitioners (OR 8.79; 95% CI 2.64-29.22).ConclusionIn several countries, additional strategies are needed to improve awareness of safety issues. DHPCs may not be sufficient to reach cardiologists when communicating safety issues of drugs outside their field.

M3 - Poster

ER -

ID: 54242929